Ulcerative Colitis | Unmet Need | US/EU | 2016

Although agents available for controlling disease in mild ulcerative colitis (UC) are largely effective and well tolerated, many unmet needs exist in treating moderate to severe disease, and sizeable opportunity remains for therapies that target this patient population. Novel agents that can more effectively induce remission, achieve mucosal healing, and/or reduce corticosteroid use relative to the leading TNF-alpha inhibitors are areas of important need. With another cell adhesion molecule (CAM) inhibitor, an oral Janus-activated kinase (Jak) inhibitor, and an oral sphingosine-1-phosphate receptor (S1P-R) inhibitor in late-stage development for moderate to severe UC, the competition in the moderate to severe UC space is intensifying; novel agents will need to differentiate themselves in efficacy or safety in order to capture appreciable market share.

launch Related Market Assessment Reports